Answers are grounded in this paper and cite their sources.
Despite success of therapies targeting the amyloid β‐protein (Aβ), the molecular identity of the forms of Aβ which contribute to Alzheimer's disease (AD) remains poorly understood. SDS‐stable Aβ dimers are present in higher‐order aggregates and exert disease‐relevant toxicity, but whether dimers form before or after large aggregates, or how dimers contribute to AD pathogenesis were previously unknown. Here, we report that covalently cross‐linked Aβ1‐42 dimers can form spontaneously upon prolonged incubation of Aβ fibrils and contain isopeptide bonds (Asp1‐Glu22 and Asp1‐Asp1), the same as those identified in dimers found in AD brain. Importantly, dimer‐enriched Aβ aggregates (DEBA) are structurally distinct to dimer‐poor aggregates (DPBA) and have enhanced resistance to proteolysis. Functionally, DEBA exhibit stronger binding to microglia, induce transcription of key pro‐inflammatory cytokines, nucleate into plaque‐like structures with microglia in vitro, and exacerbate amyloid deposition in App NL‐F/NL‐F mice. DEBA do not appear to be overtly neurotoxic, whereas solubilized DEBA induce toxicities reminiscent of that caused by Aβ‐containing AD brain extract. These findings demonstrate prolonged incubation of fibrillar Aβ aggregates results in spontaneous formation of cross‐linked dimers, and this is associated with changes in aggregate morphology and emergence of multiple disease‐relevant activities.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: